What's behind this double-digit move lower? Celldex's shares appear to have gotten caught up in the marketwide downturn last month. The biotech, after all, didn't release any material news to speak of during the course of February. Celldex
March has been a good month so far for Celldex Therapeutics (NASDAQ: CLDX) shareholders. The stock is up more than 20% this month, including a big jump last week that stemmed primarily from investor anticipation of the release of …
The decrease was primarily driven by fourth quarter cash used in operating activities of $19.5 million and partially offset by $18.4 million in net proceeds from sales of common stock under the Cantor agreement. At December 31, 2017, …
That said, it would also leave Celldex with three candidates in mid-stage clinical trials, plus two more in early-stage trials. With plenty of fallback candidates acting as a safety net, the stock looks like a buy right now. 10 stocks we like better …
And while Tesla could remain a big winner, it's not the only stock investors who are looking for big returns should consider. Case in point: Three Motley Fool investors think Celldex Therapeutics, Inc. (NASDAQ: CLDX), Tencent Holdings Ltd …
A year ago, they were trading at $3.46. This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on CLDX at https://www.zacks.com/ap/CLDX
Yahoo!1mon
Wall Street thinks that the clinical-stage biotech Celldex Therapeutics (NASDAQ: CLDX) could be a top-performing stock this year. The average 12-month price target on the stock, after all, implies a noteworthy 260% upside potential from …